Literature DB >> 25070628

Survivin depletion inhibits tumor growth and enhances chemosensitivity in hepatocellular carcinoma.

Yvonne Y Y Or1, Ariel K M Chow1, Lui Ng1, Sheung Tat Fan1, Thomas C C Yau1, Ronnie T P Poon1, Roberta W C Pang1.   

Abstract

Survivin is a member of the inhibitor of apoptosis family, which has been suggested to be crucial in the control of cell division and inhibition of apoptosis. Expression of this protein has been observed in transformed cell lines and human tumor tissues, including those from colorectal cancer, but not in terminally differentiated adult tissues. Survivin mRNA expression has frequently been detected in hepatocellular carcinoma (HCC) and its protein expression has been demonstrated to be highly correlated with proliferation index rather than apoptotic index. The present study aimed to analyze the effect of survivin on the tumorigenicity and chemosensitivity of HCC via the establishment of an HCC cell line (PLC/PRF/5) with the stable knockdown of the survivin gene (PLC‑k3). This cell line displayed significantly lower rates of survival and proliferation in assays of cell viability and proliferation, respectively, compared with those of the control cell line (PLC‑v). In addition, PLC‑k3 cells were more sensitive to cisplatin treatment, resulting in S phase arrest. These findings were further confirmed by an in vivo experiment. The data of the present study suggest that survivin is critical in promoting cell proliferation but not in inhibition of apoptosis, and enhances the chemosensitivity of HCC. Thus, the suppression of survivin expression in combination with cisplatin may contribute to the development of more effective treatments for HCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25070628     DOI: 10.3892/mmr.2014.2413

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  9 in total

Review 1.  Apoptosis in liver carcinogenesis and chemotherapy.

Authors:  Joaquim Moreno-Càceres; Isabel Fabregat
Journal:  Hepat Oncol       Date:  2015-11-11

2.  Repeated-measures implication of hepatocellular carcinoma biomarkers in living donor liver transplantation.

Authors:  King-Wah Chiu; Toshiaki Nakano; Kuang-Den Chen; Li-Wen Hsu; Chia-Yun Lai; Ching-Yin Huang; Yu-Fan Cheng; Shigeru Goto; Chao-Long Chen
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

3.  Induction of autophagy and autophagy-dependent apoptosis in diffuse large B-cell lymphoma by a new antimalarial artemisinin derivative, SM1044.

Authors:  Chunyan Cheng; Tao Wang; Zhiqun Song; Lijun Peng; Mengqing Gao; Olivier Hermine; Sophie Rousseaux; Saadi Khochbin; Jian-Qing Mi; Jin Wang
Journal:  Cancer Med       Date:  2017-12-26       Impact factor: 4.452

4.  SIRT6 Depletion Sensitizes Human Hepatoma Cells to Chemotherapeutics by Downregulating MDR1 Expression.

Authors:  Yang Q Xia; Ren J Hua; Chen Juan; Zhou H Zhong; Cheng S Tao; Ren Fang; He Lin; Gong Rui; Chen Yong
Journal:  Front Pharmacol       Date:  2018-03-06       Impact factor: 5.810

5.  Accumulation of AGO2 Facilitates Tumorigenesis of Human Hepatocellular Carcinoma.

Authors:  Yang Yang; Qi Mei
Journal:  Biomed Res Int       Date:  2020-04-30       Impact factor: 3.411

6.  Enhanced fluorescence/magnetic resonance dual imaging and gene therapy of liver cancer using cationized amylose nanoprobe.

Authors:  Hanchen Zhang; Li Deng; Haiqing Liu; Siyao Mai; Ziliang Cheng; Guangzi Shi; Hong Zeng; Zhuo Wu
Journal:  Mater Today Bio       Date:  2022-02-15

7.  A centrosome clustering protein, KIFC1, predicts aggressive disease course in serous ovarian adenocarcinomas.

Authors:  Karuna Mittal; Da Hoon Choi; Sergey Klimov; Shrikant Pawar; Ramneet Kaur; Anirban K Mitra; Meenakshi V Gupta; Ralph Sams; Guilherme Cantuaria; Padmashree C G Rida; Ritu Aneja
Journal:  J Ovarian Res       Date:  2016-03-18       Impact factor: 4.234

8.  Immunotherapy of patient with hepatocellular carcinoma using cytotoxic T lymphocytes ex vivo activated with tumor antigen-pulsed dendritic cells.

Authors:  Ying Wang; Xijing Yang; Yi Yu; Zenghui Xu; Yan Sun; Hui Liu; Jingbo Cheng; Min Liu; Bibo Sha; Linfang Li; Na Ding; Zhong Li; Huajun Jin; Qijun Qian
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

9.  Pan-cancer analysis identifies BIRC5 as a prognostic biomarker.

Authors:  Anna Fäldt Beding; Peter Larsson; Khalil Helou; Zakaria Einbeigi; Toshima Z Parris
Journal:  BMC Cancer       Date:  2022-03-25       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.